MK-4

MK-4 is a short-chain menaquinone whose primary bioactive mechanism involves serving as a cofactor for gamma-glutamyl carboxylase, enabling gamma-carboxylation of vitamin K-dependent proteins such as osteocalcin and matrix Gla protein, and is also biosynthesized in tissues via UBIAD1-mediated geranylgeranylation of menadiol. At pharmacological oral doses of 1500 µg/day, MK-4 improves osteocalcin carboxylation, though single doses up to 420 µg and 7-day regimens of 60 µg/day fail to produce detectable serum increases in healthy women, underscoring its unique tissue-targeted rather than serum-mediated pharmacokinetics.

Origin & History

MK-4 (menatetrenone) is not obtained directly from a single geographic source but is biosynthesized in animal tissues worldwide through enzymatic conversion of dietary phylloquinone (vitamin K1). It accumulates preferentially in specific tissues including the testes, pancreas, arterial walls, and brain of vertebrates, rather than circulating abundantly in serum. Dietary sources include animal-derived foods such as meat, liver, eggs, and dairy products, with no significant bacterial fermentation pathway unlike longer-chain menaquinones such as MK-7.

Historical & Cultural Context

MK-4 has no documented history of use in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or European herbalism, as the compound was not identified or isolated until the mid-twentieth century. The vitamin K family was first described by Henrik Dam in 1929 in relation to a hemorrhagic disease in chickens, with the structural distinction between K1 and K2 forms established through subsequent biochemical research in the 1940s–1960s. MK-4's clinical identity as menatetrenone emerged from Japanese pharmaceutical research, where it was developed and approved as an osteoporosis treatment, reflecting Japan's long-standing integration of micronutrient-based therapies into mainstream clinical practice. Unlike MK-7, which has a cultural association with the traditional Japanese fermented food natto, MK-4 has no analogous food-cultural heritage and is regarded primarily as a pharmaceutical or synthetic nutritional compound.

Health Benefits

- **Bone Protein Carboxylation**: MK-4 activates osteocalcin via gamma-carboxylation, enabling calcium binding in bone matrix; doses of 1500 µg/day are required to measurably improve carboxylation status, as confirmed in dose-finding trials by Takeuchi et al.
- **Tissue-Specific Accumulation**: Unlike MK-7, MK-4 accumulates directly in testes, pancreas, arterial walls, and nervous tissue through local UBIAD1-mediated biosynthesis, suggesting organ-protective roles independent of circulating serum levels.
- **Vascular Calcification Inhibition**: Through carboxylation of matrix Gla protein (MGP) in arterial walls, MK-4 may inhibit pathological calcium deposition in vascular smooth muscle; this mechanism is shared with other K2 forms but MK-4's local tissue synthesis positions it uniquely at arterial sites.
- **Antioxidant Activity**: The naphthoquinone ring structure of MK-4 confers intrinsic antioxidant capacity, allowing it to scavenge reactive oxygen species and potentially protect cell membranes in tissues where it accumulates at high concentrations.
- **Osteoporosis Management (Pharmacological Use)**: Menatetrenone (MK-4) is approved in Japan at doses of 45 mg/day (45,000 µg/day) for osteoporosis treatment, with clinical evidence supporting reductions in vertebral fracture risk in postmenopausal women at these pharmacological doses.
- **Coagulation Cascade Support**: As a functional vitamin K2 form, MK-4 supports hepatic gamma-carboxylation of clotting factors II, VII, IX, and X, though longer-chain MKs such as MK-7 demonstrate greater potency for extrahepatic coagulation factor support at nutritional doses.
- **Neuroprotective Potential**: MK-4 is the predominant K2 vitamer in brain tissue and is hypothesized to support sphingolipid synthesis and myelination, with preclinical evidence suggesting roles in neurological function, though human clinical data remain limited.

How It Works

MK-4 functions as an essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), facilitating post-translational gamma-carboxylation of glutamic acid residues on vitamin K-dependent proteins (VKDPs) including osteocalcin, matrix Gla protein, and coagulation factors; during this reaction, MK-4 is oxidized to its epoxide form and must be recycled by vitamin K epoxide reductase (VKORC1) to maintain the active hydroquinone pool. Endogenous biosynthesis of MK-4 proceeds through a three-step enzymatic pathway: phylloquinone's phytyl tail is cleaved by an unidentified enzyme to yield menadione (vitamin K3), menadione is reduced to menadiol by NAD(P)H:quinone oxidoreductase 1 (NQO1), and menadiol is then geranylgeranylated by the prenyltransferase UBIAD1 using geranylgeranyl pyrophosphate (GGPP) as the prenyl donor, producing menaquinol-4. Beyond carboxylation, MK-4 has been identified as a ligand for the steroid and xenobiotic receptor (SXR/PXR), through which it may regulate transcription of genes involved in bone metabolism and cell survival. The short four-isoprene side chain renders MK-4 highly hydrophobic and facilitates rapid cellular uptake into tissues but simultaneously limits its incorporation into lipoprotein particles, explaining its negligible serum presence after physiological or low pharmacological oral doses.

Scientific Research

The clinical evidence base for MK-4 at nutritional supplemental doses is limited, consisting primarily of small pharmacokinetic studies and dose-finding trials without published effect sizes (Cohen's d) or formal power calculations. Key pharmacokinetic studies in healthy Japanese females demonstrate that single oral doses of 420 µg and 7-day consecutive doses of 60 µg/day produce undetectable serum MK-4 (0.00 ± 0.77 ng/mL), contrasting sharply with MK-7's robust 48-hour serum persistence, while a comparative absorption study using 900 µg showed MK-4 had both a shorter serum half-life and smaller area under the curve than vitamin K1 or MK-9. Dose-finding work by Takeuchi et al. in healthy subjects established that 500 µg/day for two months had no measurable effect on osteocalcin carboxylation, whereas 1500 µg/day produced improvement, providing a functional threshold but without large-scale RCT replication. The strongest clinical evidence for MK-4 exists at pharmacological doses (45 mg/day as menatetrenone) used in Japanese osteoporosis trials, where RCTs have demonstrated fracture risk reduction, but these findings are not directly applicable to typical dietary supplement dosing contexts in Western markets.

Clinical Summary

The most rigorous clinical data for MK-4 derive from its use as the pharmaceutical agent menatetrenone at 45 mg/day (45,000 µg/day) for postmenopausal osteoporosis in Japan, where randomized controlled trials have reported reductions in vertebral fracture incidence, though many of these trials were conducted in Japan with specific dietary backgrounds and have not been uniformly replicated in Western cohorts. At nutritional supplemental doses (60–500 µg/day), clinical trials consistently fail to demonstrate measurable increases in serum MK-4 or improvements in carboxylated osteocalcin, establishing a clear dose-response threshold around 1500 µg/day for any detectable biochemical effect. Comparative pharmacokinetic studies confirm MK-4's inferiority to MK-7 for serum bioavailability and sustained carboxylation support at equivalent microgram doses, suggesting that for circulating biomarker endpoints, MK-7 is the preferred supplemental K2 form. Confidence in MK-4's benefits at supplemental doses below 1500 µg/day is low; confidence in the pharmacological 45 mg/day dose for bone endpoints is moderate, constrained by population-specific trial designs and limited independent replication.

Nutritional Profile

MK-4 is a pure lipophilic micronutrient compound with the molecular formula C31H40O2 and molecular weight of 444.65 g/mol; it contributes no caloric macronutrients, protein, carbohydrate, or fiber. Dietary concentrations in animal foods are low and variable: liver and certain organ meats contain the highest tissue concentrations, while muscle meat, eggs, and dairy provide smaller amounts; precise food-level concentrations are not consistently tabulated in standard nutrient databases due to analytical challenges. Bioavailability is highly context-dependent: intestinal absorption requires bile acids and dietary fat for micellar incorporation, and once absorbed via the lymphatic system, MK-4 is rapidly cleared from serum and partitioned into peripheral tissues. The compound's partition into tissues such as testes, pancreas, and brain means that serum levels are a poor proxy for tissue status, complicating nutritional assessment and supplementation monitoring.

Preparation & Dosage

- **Oral Capsule/Tablet (Nutritional Supplement)**: Doses of 1500 µg/day (1.5 mg/day) represent the minimum threshold for measurable improvement in osteocalcin carboxylation based on clinical dose-finding data; doses of 60–500 µg/day have not demonstrated serum detectability or functional biomarker changes.
- **Pharmaceutical Menatetrenone (Japan)**: Approved at 45 mg/day (45,000 µg/day) in three divided doses of 15 mg for osteoporosis treatment; this is a prescription pharmacological dose and is not representative of nutritional supplementation.
- **Soft-Gel Formulation with Fat**: MK-4 is a fat-soluble compound and should be administered with a fat-containing meal to optimize intestinal absorption; co-ingestion with dietary fat enhances micellar solubilization and lymphatic transport.
- **Synthetic Supplement Form**: Menatetrenone USP reference standard is produced synthetically from menadione via geranylgeranylation; supplement-grade MK-4 is typically derived from the same synthetic route rather than fermentation.
- **Dosing Frequency**: Due to its short serum half-life relative to MK-7, MK-4 at pharmacological doses is administered in divided doses (e.g., three times daily) to maintain tissue exposure; single daily dosing may be insufficient at lower supplemental ranges.
- **Standardization**: No internationally recognized standardization percentage applies; purity is defined by USP or equivalent pharmacopoeial monographs specifying ≥97% menatetrenone content by HPLC.

Synergy & Pairings

MK-4 demonstrates functional synergy with vitamin D3 (cholecalciferol) in bone metabolism: vitamin D3 upregulates osteocalcin gene transcription while MK-4 enables post-translational gamma-carboxylation of the resulting osteocalcin protein, making both compounds necessary for fully functional bone Gla protein activity. Co-administration with magnesium may support the broader mineralization cascade, as magnesium is required for osteoblast function and serves as a cofactor in enzymes involved in vitamin K recycling. The combination of MK-4 with MK-7 has been proposed to leverage MK-4's rapid tissue uptake alongside MK-7's sustained serum half-life and superior extrahepatic carboxylation capacity, potentially offering complementary tissue coverage, though direct head-to-head combination trials in humans are lacking.

Safety & Interactions

At supplemental doses up to 1500 µg/day and in pharmacokinetic trials up to 900 µg single doses, no adverse events have been reported in published studies; the pharmacological menatetrenone dose of 45 mg/day has been used in clinical trials without significant safety signals, though comprehensive long-term safety data at this dose are not as extensive as for many pharmaceutical agents. As a vitamin K2 form, MK-4 carries the class-wide interaction risk with vitamin K antagonist anticoagulants (e.g., warfarin, acenocoumarol): concurrent use can reduce anticoagulant efficacy by competing at the VKORC1 enzyme, and patients on these medications should consult a physician before using any vitamin K supplement. No specific teratogenicity data exist for MK-4 supplementation in pregnancy; general vitamin K guidelines suggest that physiological doses are unlikely to pose risk, but pharmacological doses during pregnancy have not been adequately studied and should be avoided without medical supervision. Individuals with rare hereditary conditions affecting vitamin K metabolism or those taking orlistat or cholestyramine (which impair fat-soluble vitamin absorption) may have altered MK-4 absorption and require monitoring.